Neumora Therapeutics, Inc. (NASDAQ:NMRA) Short Interest Update

Neumora Therapeutics, Inc. (NASDAQ:NMRA) was the recipient of a large decrease in short interest during the month of February. As of February 27th, there was short interest totaling 5,216,610 shares, a decrease of 13.7% from the February 12th total of 6,045,735 shares. Based on an average daily volume of 870,409 shares, the days-to-cover ratio is presently 6.0 days. Currently, 4.3% of the shares of the company are short sold. Currently, 4.3% of the shares of the company are short sold. Based on an average daily volume of 870,409 shares, the days-to-cover ratio is presently 6.0 days.

Insider Activity at Neumora Therapeutics

In other news, insider Paul L. Berns sold 9,819 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $3.51, for a total value of $34,464.69. Following the transaction, the insider owned 7,395,185 shares in the company, valued at $25,957,099.35. This represents a 0.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders have sold 23,387 shares of company stock worth $82,647. 26.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Siren L.L.C. grew its position in shares of Neumora Therapeutics by 44.3% during the fourth quarter. Siren L.L.C. now owns 6,288,783 shares of the company’s stock valued at $11,257,000 after purchasing an additional 1,930,500 shares in the last quarter. Millennium Management LLC lifted its position in shares of Neumora Therapeutics by 80.1% in the fourth quarter. Millennium Management LLC now owns 3,616,514 shares of the company’s stock worth $6,474,000 after buying an additional 1,608,266 shares in the last quarter. Ikarian Capital LLC boosted its stake in Neumora Therapeutics by 10,128.9% during the fourth quarter. Ikarian Capital LLC now owns 1,278,408 shares of the company’s stock valued at $2,288,000 after buying an additional 1,265,910 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Neumora Therapeutics during the third quarter valued at approximately $1,512,000. Finally, Marshall Wace LLP purchased a new position in Neumora Therapeutics during the 4th quarter valued at approximately $1,045,000. Institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Price Performance

Shares of NASDAQ:NMRA opened at $2.64 on Thursday. The company has a market capitalization of $441.12 million, a P/E ratio of -1.80 and a beta of 2.49. Neumora Therapeutics has a 1-year low of $0.61 and a 1-year high of $3.65. The firm’s 50 day simple moving average is $2.69 and its two-hundred day simple moving average is $2.27. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.85 and a quick ratio of 6.85.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Royal Bank Of Canada raised shares of Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and upped their target price for the company from $4.00 to $7.00 in a report on Monday, December 1st. William Blair upgraded shares of Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Neumora Therapeutics in a research report on Thursday, January 22nd. Mizuho set a $6.00 target price on Neumora Therapeutics in a report on Monday, January 5th. Finally, Leerink Partners assumed coverage on Neumora Therapeutics in a research report on Monday, January 12th. They set an “outperform” rating and a $8.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, Neumora Therapeutics currently has an average rating of “Hold” and an average target price of $6.71.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.